Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713284 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
A Phase 4 study of Renal Transplantation, sponsored by California Pacific Medical Center Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00713284 is a Phase 4 study of Renal Transplantation that has completed, run by California Pacific Medical Center Research Institute. The registered enrollment target is 29 participants, below the 47-participant average among 7 other Renal Transplantation trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00713284, a Phase 4 study of Renal Transplantation, has completed, sponsored by California Pacific Medical Center Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
Conditions Studied
Interventions
- DRUG sirolimus
Study Locations (1)
California
- California Pacific Medical Center; Barry S. Levin, MD Department of Transplantation - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00713284
The ClinicalTrials.gov registry entry for NCT00713284 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 7 other Renal Transplantation trials with a reported enrollment target (38% lower). The listed sponsor is California Pacific Medical Center Research Institute, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Transplantation appearing as the primary indexed condition, and to 1 intervention - of which sirolimus is the first listed.
NCT00713284 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00713284 about?
NCT00713284 is a clinical study titled "Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic". The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
What is the current status of trial NCT00713284?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2007-05. Estimated completion is 2010-11.
What conditions does trial NCT00713284 study?
This clinical trial studies the following conditions: Renal Transplantation.
What interventions are being tested in trial NCT00713284?
The interventions under investigation include: sirolimus (DRUG).
Who is sponsoring clinical trial NCT00713284?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00713284 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Envarsus XR® in Adolescent Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
A Study of TCD601 in de Novo Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Tolerance by Engaging Antigen During Cellular Homeostasis
COMPLETED · Phase 1
-
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
COMPLETED
-
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.